Characteristics of the first immunocompromised patients to receive sipavibart as an early access treatment for COVID-19 pre-exposure prophylaxis in France
France was the first country to grant Sipavibart (AZD3152, an investigational long-acting monoclonal antibody) as a COVID-19 pre-exposure prophylaxis treatment in immunocompromised individuals in December 2023. The first patients to receive Sipavibart had different profiles, but they were all highly...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Book |
| Published: |
Taylor & Francis Group,
2024-12-01T00:00:00Z.
|
| Subjects: | |
| Online Access: | Connect to this object online. |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
MARC
| LEADER | 00000 am a22000003u 4500 | ||
|---|---|---|---|
| 001 | doaj_1e33f7c4698e4801b92f13b3d35ed9e6 | ||
| 042 | |a dc | ||
| 100 | 1 | 0 | |a Paul Loubet |e author |
| 700 | 1 | 0 | |a Benjamin Gaborit |e author |
| 700 | 1 | 0 | |a Mathilde Salpin |e author |
| 700 | 1 | 0 | |a Hèlene Gardeney |e author |
| 700 | 1 | 0 | |a Ilies Benotmane |e author |
| 700 | 1 | 0 | |a Thomas Systchenko |e author |
| 245 | 0 | 0 | |a Characteristics of the first immunocompromised patients to receive sipavibart as an early access treatment for COVID-19 pre-exposure prophylaxis in France |
| 260 | |b Taylor & Francis Group, |c 2024-12-01T00:00:00Z. | ||
| 500 | |a 10.1080/21645515.2024.2387221 | ||
| 500 | |a 2164-554X | ||
| 500 | |a 2164-5515 | ||
| 520 | |a France was the first country to grant Sipavibart (AZD3152, an investigational long-acting monoclonal antibody) as a COVID-19 pre-exposure prophylaxis treatment in immunocompromised individuals in December 2023. The first patients to receive Sipavibart had different profiles, but they were all highly immunocompromised with frequently associated hypogammaglobulinemia and other chronic conditions. No adverse event was reported. | ||
| 546 | |a EN | ||
| 690 | |a COVID-19 | ||
| 690 | |a prophylaxis | ||
| 690 | |a immunocompromised | ||
| 690 | |a Immunologic diseases. Allergy | ||
| 690 | |a RC581-607 | ||
| 690 | |a Therapeutics. Pharmacology | ||
| 690 | |a RM1-950 | ||
| 655 | 7 | |a article |2 local | |
| 786 | 0 | |n Human Vaccines & Immunotherapeutics, Vol 20, Iss 1 (2024) | |
| 787 | 0 | |n https://www.tandfonline.com/doi/10.1080/21645515.2024.2387221 | |
| 787 | 0 | |n https://doaj.org/toc/2164-5515 | |
| 787 | 0 | |n https://doaj.org/toc/2164-554X | |
| 856 | 4 | 1 | |u https://doaj.org/article/1e33f7c4698e4801b92f13b3d35ed9e6 |z Connect to this object online. |